We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
BCG vaccine for immunotherapy in warts: is it really safe in a tuberculosis endemic area?
- Authors
Daulatabad, Deepashree; Pandhi, Deepika; Singal, Archana
- Abstract
ABSTRACT Management of recurrent and or recalcitrant warts can be a therapeutic challenge and in such cases invoking body's own immunity may help to overcome the present episode and also prevent recurrences. Bacilli Calmette Geurin (BCG) immunotherapy has long been considered to be an effective and safe modality in such cases. We present a series of seven cases treated with BCG immunotherapy wherein a single dose of BCG caused regression of wart in 85.7% patients and complete resolution was evident in 28.6% patients. However, the development of adverse effects precluded any further dosages in four of seven (57.1%) patients. This raises serious concern on the safety of this therapeutic modality, especially in a population endemic to tuberculosis.
- Subjects
BCG vaccines; IMMUNOTHERAPY; WARTS treatment; TUBERCULOSIS vaccines; DRUG dosage
- Publication
Dermatologic Therapy, 2016, Vol 29, Issue 3, p168
- ISSN
1396-0296
- Publication type
Article
- DOI
10.1111/dth.12336